IN THIS ISSUE

COVID-19 vaccines and treatments 1
Cancer 2
Dermatology 2
Diabetes 3
Gastro-intestinal system 3
Haematology 3
Hormone system 3
Immune system 3
Metabolic disorders 4
Nephrology 4
Nervous system 4
Ophthalmology 4
Respiratory system 5
Rheumatology 5
Other medicines 5
Medicines under additional monitoring 5
Guidelines 5
Scientific committee and working party activities 6
COVID-19 6
Other publications 7
Events 7
Explanation of terms used 8

This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Information is selected based on recommendations from consulted patients, consumers and healthcare professionals, and does not necessarily cover all relevant information published by the Agency.

To receive each new issue of the newsletter, please click here RSS feeds, choose 'Human medicines highlights newsletter' and then click on 'Subscribe to this feed'. Please note, in order to be able to view RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to our RSS guide and follow the instructions from the selected RSS reader in order to add our newsletter feed.

You can find details on how to cancel / unsubscribe to an RSS feed on the RSS reader tool that you are using, for example Unsubscribe from an RSS Feed for users of Microsoft Outlook.

For further information on the processing of your personal data, please find EMA's Privacy statement regarding the sending of electronic newsletters click here.

Information on medicines

COVID-19 vaccines and treatments

Ongoing evaluations

- EMA evaluating the use of COVID-19 Vaccine Moderna in young people aged 12 to 17
- COVID-19 Vaccine Janssen: authorities in EU take steps to safeguard vaccine quality
- COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis
- Vaxzevria: EMA advises against use in people with history of capillary leak syndrome

Safety update

- COVID-19 vaccine safety update for Comirnaty: 18 June 2021
- COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 18 June 2021

Direct Healthcare Professional Communication (DHPC)

Risk of thrombosis in combination with thrombocytopenia - Updated information

Vaxzevria (previously COVID-19 Vaccine AstraZeneca): contraindication in individuals with previous capillary leak syndrome

Positive CHMP opinions on new medicines

- Abecma (idecabtagene vilocel)
  Treatment of multiple myeloma (cancer of the bone marrow)

- Abiraterone Mylan (abiraterone acetate) generic of Zytiga
  Treatment of metastatic prostate cancer

- Minjuvi (tafasitamab)
  Treatment of relapsed or refractory diffuse large B-cell lymphoma (blood cancer)

New medicines authorised

- Inrebic (fedratinib)
  Treatment of myelofibrosis (a rare form of blood cancer)

- Onureg (azacitidine)
  Treatment of acute myeloid leukaemia (a cancer of white blood cells)

- Minjuvi (tafasitamab)
  Treatment of capillary leak syndrome

- Minjuvi (tafasitamab)
  Treatment of relapsed or refractory diffuse large B-cell lymphoma (blood cancer)

New information on authorised medicines

- Opdivo (nivolumab) - new indication
  Treatment of several types of cancer

Direct Healthcare Professional Communication (DHPC)

- Venclyxto - (venetoclax) film coated tablets: Updated recommendations on tumour lysis syndrome (TLS) in CLL patients

Dermatology (skin conditions)

Positive CHMP opinions on new medicines

- Bimzelx (bimekizumab)
  Treatment of plaque psoriasis (scaly patches on skin)

New medicines authorised

- Adtralza (tralokinumab)
  Treatment of moderate to severe atopic dermatitis (also known as eczema, when the skin is itchy, red and dry)
Diabetes

New information on authorised medicines

- Edistride and Forxiga (dapagliflozin) - new indication
  Treatment of diabetes mellitus, type 1 and 2

Gastro-intestinal system

Negative CHMP opinions on new medicines

- Flynpovi (eflornithine / sulindac)
  Intended for the treatment of familial adenomatous polyposis (growths in the large intestine that can become cancerous)

Haematology (blood conditions)

Positive CHMP opinions on new medicines

- Evrenzo (roxadustat)
  Treatment of anaemia symptoms in patients with chronic kidney disease

New medicines authorised

- Inrebi (fedratinib)
  Treatment of myelofibrosis (a rare form of blood cancer)
- Onureq (azacitidine)
  Treatment of acute myeloid leukaemia, a cancer of white blood cells

Hormone system

New medicines authorised

- Drovelis (estetrol /drospirenone)
  Combined contraceptive pill
- Lydisilka (estetrol/drospirenone)
  Combined contraceptive pill

Immune system

New medicines authorised

- Enspryn (satralizumab)
  Treatment of neuromyelitis optica spectrum disorders (inflammatory disorders that affect mainly the optic nerve which connects the eye to the brain, and the spinal cord)
- Orladeyo (berotralstat)
  Treatment of hereditary angioedema (swelling beneath the skin)
New information on authorised medicines

- **Rinvoq** (*upadacitinib*) - new indication
  Treatment of rheumatoid arthritis (a disease that causes inflammation of the joints)

- **Xeljanz** (*tofacitinib*) - new indication
  Treatment of rheumatoid arthritis (a disease that causes inflammation of the joints) and psoriatic arthritis (red, scaly patches on the skin with inflammation of the joints)

Metabolic disorders

New information on authorised medicines

- **Galafold** (*migalastat*) - extension of indication
  Treatment of Fabry Disease (a rare lysosomal storage disorder)

Nephrology (kidney conditions)

Positive CHMP opinions on new medicines

- **Evrenzo** (*roxadustat*)
  Treatment of anaemia symptoms in patients with chronic kidney disease

Direct Healthcare Professional Communication (DHPC)

- **INOmax** (nitric oxide): Difficulties in closing the cylinder valves after use; precautions for use when disconnecting the cylinders from pressure regulators

Nervous system

Positive CHMP opinions on new medicines

- **Fingolimod Mylan** (*fingolimod*)
  Treatment of multiple sclerosis

New medicines authorised

- **Ponyvory** (*ponesimod*)
  Treatment of multiple sclerosis

Safety update

- Review of **Stresam** (*etifoxine*) - review started - *Art. 31*
  Treatment of anxiety disorders

Ophthalmology (eye conditions)

Positive CHMP opinions on new medicines

- **Byooviz** (*ranibizumab*)
  Treatment of eye problems caused by damage to the retina

Key to symbols used

- O Orphan medicine
- 🟢 Generic medicine
- 🟡 Biosimilar medicine
- C Conditional approval
- E Exceptional circumstances
Respiratory system

Withdrawal of applications for extension of indication

- **Esbriet** *(pirfenidone)*
  Treatment of idiopathic pulmonary fibrosis (fibrous scar tissue which forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath)

Rheumatology (immune and inflammatory conditions)

New information on authorised medicines

- **Rinvoq** *(upadacitinib)* - new indication
  Treatment of rheumatoid arthritis (a disease that causes inflammation of the joints)

- **Xeljanz** *(tofacitinib)* - new indication
  Treatment of rheumatoid arthritis (a disease that causes inflammation of the joints) and psoriatic arthritis (red, scaly patches on the skin with inflammation of the joints)

Other medicines

Positive CHMP opinions on new medicines

- **Voxzogo** *(vosoritide)*
  Treatment of achondroplasia, a condition that impairs bone growth and causes dwarfism.

New medicines authorised

- **Efmody** *(hydrocortisone)*
  Treatment of an inherited condition called congenital adrenal hyperplasia

Medicines under additional monitoring

- [Updated list of medicines under additional monitoring](#)

Other information

Guidelines

Guidelines open for consultation

- **ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 2b**
  Deadline for comments: 24 October 2021

- **Concept paper for the revision of residues guidelines to align with the definitions for withdrawal periods provided in Regulation (EU) 2019/6**
  Deadline for comments: 31 July 2021
• **Draft guideline on data requirements for vaccine antigen master files (VAMF)**
  Deadline for comments: 30 September 2021

**Adopted guidelines**

• **Deferasirox, dispersible tablets (125 mg, 250 mg and 500 mg), film-coated tablets (90 mg, 180 mg, and 360 mg) and granules (90 mg, 180 mg and 360 mg) product-specific bioequivalence guidance**

• **ICH guideline work to advance Patient Focused Drug Development (PFDD)**

• **ICH guideline E6 on good clinical practice - Draft ICH E6 principles**

**Scientific committee and working party activities**

• **Medicinal products for human use: monthly figures - May 2021**

• **CAT - agendas, minutes and reports**

• **CHMP - agendas, minutes and reports**

• **CHMP - applications for new human medicines: June 2021**

• **COMP - agendas, minutes and meetings reports**

• **HMPC - agendas, minutes and meetings reports**

• **PDCO - agendas, minutes and meeting reports**

• **PRAC - agendas, minutes and highlights**

• **PRAC statistics: June 2021**

• **PRAC recommendations on safety signals**

• **PCWP and HCPWP joint virtual meeting - 1 and 2 June 2021 - Minutes**

**COVID-19**

• **Additional manufacturing site for COVID-19 Vaccine Janssen**

• **Additional manufacturing capacity for Moderna’s COVID-19 vaccine**

• **Additional manufacturing capacity for BioNTech/Pfizer’s COVID-19 vaccine**

• **EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome**

• **Advancing international collaboration on COVID-19 real-world evidence and observational studies**

• **International regulators and WHO address need to boost COVID-19 vaccine confidence**
Other publications

- Deputy Executive Director Noël Wathion retires after 25 years of service
- Highlights of Management Board: June 2021 meeting
- EMA and EUnetHTA take stock of their cooperation
- EU regulators develop recommendations to forecast demand of medicines
- Annual report 2020 published
- Use of antibiotics in animals is decreasing
- Update of EU recommendations for 2021–2022 seasonal flu vaccine composition
- Success rate for marketing authorisation applications from SMEs doubles between 2016 and 2020
- Strengthening Training of Academia in Regulatory Science (STARS) overview
- Report on budgetary and financial management: financial year 2020
- Report on budgetary and financial management: financial year 2019
- Report on budgetary and financial management: financial year 2018

Events

- EMA regular press briefing on COVID-19 - Virtual meeting - 1 July 2021
- EMA regular press briefing on COVID-19 - Virtual meeting - 17 June 2021
- Sixth industry stakeholder platform on research and development support - Virtual meeting - 4 June 2021
- ePI information workshop and exploratory workshop - Virtual meeting - From 5 July to 8 July 2021 - Agenda 5 July - Agenda 6 - 8 July
- Sixth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines - virtual meeting - 30 June 2021 - Agenda

Key to symbols used

- Orphan medicine
- Generic medicine
- Biosimilar medicine
- Conditional approval
- Exceptional circumstances
Explanation of terms used

**Orphan medicine**
A medicine intended for the treatment of a rare, serious disease. These medicines are granted orphan status during their development; at time of approval, orphan designations are reviewed to determine whether the information available to date allows maintaining the medicine’s orphan status.

**Generic medicine**
A medicine that is essentially the same as one that has already been authorised for use. (The latter is known as the ‘reference medicine’)

**Biosimilar medicine**
A biological medicine that is similar to another biological medicine which has already been authorised for use. (Biosimilar medicines are also known as ‘similar biological’ medicines)

**Conditional approval**
A medicine that fulfils an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorisation on the basis of less complete clinical data than are normally required, subject to specific obligations being imposed on the authorisation holder to generate complete data on the medicine.

**Exceptional circumstances**
A medicine may be approved in some cases where the applicant cannot provide comprehensive data on the safety or efficacy of the medicine under normal conditions of use, due to exceptional circumstances such as ethical issues or the rarity of the disease concerned. These medicines are subject to specific post-authorisation obligations and monitoring.

**Medicines assessed under Article 58**
Article 58 of Regulation (EC) No 726/2004 allows the CHMP to give opinions, in co-operation with the World Health Organization, on medicinal products that are intended exclusively for markets outside of the European Union.

---

**Note on the centralised authorisation procedure**
To obtain a single marketing authorisation (licence) for a medicine that is valid in all Member States of the European Union (EU) – via a process known as the ‘centralised procedure’ – the company or person developing the medicine must submit an application to the European Medicines Agency. The Agency’s Committee for Medicinal Products for Human Use (CHMP) carries out a scientific evaluation of the information contained in the application and prepares an opinion (scientific recommendation). The Agency transmits this (positive or negative) opinion to the European Commission, which then issues a Decision granting or refusing the marketing authorisation. When the CHMP adopts a positive opinion on a medicine, the Agency publishes on its website a ‘summary of opinion’, in the first instance, followed by more detailed information in a ‘European public assessment report (EPAR)’ after the marketing authorisation has been granted.

**Visit our website**
Further information about the European Medicines Agency and the work it does is available on our website:
http://www.ema.europa.eu
In particular, you may be interested in these links:
About us
Patients and carers
Healthcare professionals
European public assessment reports
If you have a question relating to the content of this Newsletter, please send it via www.ema.europa.eu/contact

---

**European Medicines Agency**
Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Website www.ema.europa.eu Telephone +31 (0)88 871 6000

© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.